Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 1;34(11):2518–2533. doi: 10.1007/s12325-017-0626-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 3 — Distribution of the treatment differences observed in all individual patients for the change from baseline in trough forced expiratory volume in 1 s (FEV₁) at week 8 [umeclidinium/vilanterol, 62.5/25 µg (UMEC/VI), minus tiotropium/olodaterol, 5/5 µg (TIO/OLO)] for the intent-to-treat (ITT) population. ∆ treatment difference in individual patients (UMEC/VI minus TIO/OLO), MCID minimal clinically important difference in trough FEV₁ (100 mL), pts patients, asterisk median treatment difference of 120 mL in favor of UMEC/VI